PHIO | Phio Pharmaceuticals Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2701 - 2.5500
52 Week Range	2.1680 - 18.81
Beta	0.58
Implied Volatility	550.73%
IV Rank	67.99%
Day's Volume	34,203
Average Volume	63,209
Shares Outstanding	1,055,218
Market Cap	2,511,419
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-05-10

Valuation
Profitability
Growth
Health
P/E Ratio	-0.24
Forward P/E Ratio	N/A
EPS	-9.75
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

PHIO's peers: ALLR, ATNF, CAPR, DRMA, DRUG, ENLV, ENSC, EVAX, GOVX, HOTH, IMRN, INM, JAGX, LEXX, MEIP, NBY, NRBO, PALI, ZURA, APGN, EFTR, IMMX, CNSP, ZVSA, VECT, AVRO, CWBR, OCEA, ELEV, SONN, CDIO, QLGN, REVB, RNAZ, SMMT, SNGX, TCBP, VTVT, VYNE, XBIO, ERNA

*Chart delayed

Analyzing fundamentals for PHIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PHIO Fundamentals page.

Watching at PHIO technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on PHIO Technicals page.